Call 08048973947 78% Response Rate

our range

Anti Cancer Injectables

Offering you a complete choice of products which include leuprolide acetate depot injection, cabazitaxel inj. and itolizummab.
Leuprolide Acetate Depot Injection

Leuprolide Acetate Depot Injection

Rs 7,999  / VialGet Best Price
Packaging Size22.5 mg 11.25;mg
BrandLuprodex,leugard
CompositionLuprodex
ManufacturerZydus cadila
TreatmentPristacance
Prescription/Non prescriptionNon prescription
Luepride. We "Ansh Enterprises" is Private Limited Company based firm Wholesale Trader of Pharmaceutical Injection, Protein Powder, Pharmaceutical Tablet, etc

View Complete details

get quote request a call back
  • Cabazitaxel Inj.
  • Cabazitaxel Inj.
  • Cabazitaxel Inj.
  • Cabazitaxel Inj.
  • Cabazitaxel Inj.
  • Cabazitaxel Inj.
Cabazitaxel Inj.

Cabazitaxel Inj.

Rs 9,000  / VialGet Best Price

Minimum Order Quantity: 1 Vial

Packaging Size60MG
ManufacturerZEE LAB
BrandKABANAT,CAZAT,CABAXAN,,JEVTANA,PROCABAZI,JEVTAXEL
CompositionKABANAT,CAZAT,CABAXAN,,JEVTANA,PROCABAZI,JEVTAXEL
Packaging60MG
Dosage FormINJECTION
TreatmentCANCER
Warning and PrecautionANTICANCER
Storage30
Cabazitaxel is an anti cancer medicine and is used in the treatment of prostate cancer that has stopped responding to other anti cancer medicines or surgery.

Additional Information:

  • Item Code: 30041010
  • Production Capacity: KABANAT,CAZAT,CABAXAN,,JEVTANA,PROCABAZI,JEVTAXEL
  • Delivery Time: 1
  • Packaging Details: KABANAT,CAZAT,CABAXAN,,JEVTANA,PROCABAZI,JEVTAXEL

View Complete details

get quote request a call back
  • Itolizummab
  • Itolizummab
Itolizummab

Itolizummab

Rs 24,999  / VialGet Best Price

Minimum Order Quantity: 1 Vial

Brand NameALYUZUMAB
ManufacturerBIOCON
Packaging TypeVIAL
BrandBIOCON
Usage/ApplicationCommercial
CompositionALTUZUMAB
Injectable FormLiquid
DoseALTUZUMAB
Packaging SizeITOLIZUMAB
Medicine TypeAllopathic
Biotechnology major Biocon says it will launch biologic drug Itolizumab for the treatment of moderate to severe coronavirus patients at a price of around 8,000 per vial. The company has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. Biocon says Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with such complications. ET's Divya Rajagopal brings you all the details

Additional Information:

  • Item Code: 30004100
  • Production Capacity: 1000
  • Delivery Time: 1 DAY

View Complete details

get quote request a call back

EXPLORE MORE CATEGORIES